In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disorder progression or perhaps the members are not able to tolerate the study drugs. For all stream cytometry experiments, ten,000 cells for every replicate were https://kamerontepam.bleepblogs.com/32439140/the-best-side-of-abbv-744-clinical-trial-phase-1-results